ZA201300062B - Hybrid light chain mice - Google Patents

Hybrid light chain mice

Info

Publication number
ZA201300062B
ZA201300062B ZA2013/00062A ZA201300062A ZA201300062B ZA 201300062 B ZA201300062 B ZA 201300062B ZA 2013/00062 A ZA2013/00062 A ZA 2013/00062A ZA 201300062 A ZA201300062 A ZA 201300062A ZA 201300062 B ZA201300062 B ZA 201300062B
Authority
ZA
South Africa
Prior art keywords
light chain
hybrid light
chain mice
mice
hybrid
Prior art date
Application number
ZA2013/00062A
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ZA201300062B publication Critical patent/ZA201300062B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA2013/00062A 2010-06-22 2013-01-03 Hybrid light chain mice ZA201300062B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22
PCT/US2011/041370 WO2011163314A1 (en) 2010-06-22 2011-06-22 Hybrid light chain mice

Publications (1)

Publication Number Publication Date
ZA201300062B true ZA201300062B (en) 2014-09-25

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
ZA2013/00063A ZA201300063B (en) 2010-06-22 2013-01-03 Mice expressing alight chain with human lambda variabe and mouse constant regions
ZA2013/00062A ZA201300062B (en) 2010-06-22 2013-01-03 Hybrid light chain mice
ZA2014/04601A ZA201404601B (en) 2010-06-22 2014-06-23 Mice expressing alight chain with human lambda variable and mouse constant regions
ZA2014/04600A ZA201404600B (en) 2010-06-22 2014-06-23 Hybrid light chain mice
ZA2015/06598A ZA201506598B (en) 2010-06-22 2015-09-07 Mice expressing alight chain with human lambda variable and mouse constant regions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA2013/00063A ZA201300063B (en) 2010-06-22 2013-01-03 Mice expressing alight chain with human lambda variabe and mouse constant regions

Family Applications After (3)

Application Number Title Priority Date Filing Date
ZA2014/04601A ZA201404601B (en) 2010-06-22 2014-06-23 Mice expressing alight chain with human lambda variable and mouse constant regions
ZA2014/04600A ZA201404600B (en) 2010-06-22 2014-06-23 Hybrid light chain mice
ZA2015/06598A ZA201506598B (en) 2010-06-22 2015-09-07 Mice expressing alight chain with human lambda variable and mouse constant regions

Country Status (31)

Country Link
US (21) US9012717B2 (lt)
EP (7) EP2568049B1 (lt)
JP (15) JP5988969B2 (lt)
KR (16) KR102193823B1 (lt)
CN (4) CN104342455B (lt)
AU (1) AU2011271046B2 (lt)
BR (3) BR112012033248A2 (lt)
CA (2) CA2804311C (lt)
CY (5) CY1117537T1 (lt)
DK (5) DK2905338T3 (lt)
ES (5) ES2576928T3 (lt)
HK (4) HK1168384A1 (lt)
HR (5) HRP20160497T1 (lt)
HU (5) HUE029692T2 (lt)
IL (11) IL300712A (lt)
LT (4) LT2480675T (lt)
ME (5) ME02442B (lt)
MX (6) MX347322B (lt)
MY (6) MY195212A (lt)
NO (1) NO2905338T3 (lt)
NZ (6) NZ605758A (lt)
PL (5) PL2480675T3 (lt)
PT (5) PT3034608T (lt)
RS (5) RS56589B1 (lt)
RU (3) RU2601297C2 (lt)
SG (4) SG10201504568YA (lt)
SI (5) SI2480676T1 (lt)
SM (3) SMT201600212B (lt)
TR (1) TR201905992T4 (lt)
WO (2) WO2011163311A1 (lt)
ZA (5) ZA201300063B (lt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
CA3038954A1 (en) 2008-09-30 2010-04-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN102292445A (zh) 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
LT3241435T (lt) * 2009-07-08 2021-10-25 Kymab Limited Gyvūnų modeliai ir terapinės molekulės
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
MX350983B (es) 2010-02-08 2017-09-27 Regeneron Pharma Raton de cadena ligera comun.
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011123708A2 (en) 2010-03-31 2011-10-06 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
NO2905338T3 (lt) 2010-06-22 2017-12-30
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
EP3960865A1 (en) * 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
RU2664232C2 (ru) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной универсальной легкой цепью
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP3527070A1 (en) 2011-12-20 2019-08-21 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
PL2825037T4 (pl) 2012-03-16 2020-03-31 Regeneron Pharmaceuticals, Inc. Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
HUE053310T2 (hu) 2012-03-16 2021-06-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
CN108611369B (zh) * 2013-03-13 2022-08-26 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
KR102150414B1 (ko) * 2013-09-18 2020-09-02 리제너론 파마슈티칼스 인코포레이티드 히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
ES2859373T3 (es) 2013-10-01 2021-10-01 Kymab Ltd Modelos animales y moléculas terapéuticas
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR20230158661A (ko) 2014-03-21 2023-11-21 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
ME03806B (me) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
PT3233912T (pt) 2014-12-19 2021-08-09 Regenesance B V Antocorpos que se ligam a c6 humano e utilizações destes
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
TR201904686T4 (tr) 2015-02-05 2019-05-21 Basf Se Bi̇r bi̇ri̇nci̇ isi transfer çevri̇mi̇ne ve bi̇r i̇ki̇nci̇ isi transfer çevri̇mi̇ne sahi̇p olan güneş enerji̇si̇ santrali̇
AU2016232715A1 (en) * 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
ES2936317T3 (es) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Anticuerpos contra OX40 y usos de los mismos
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
SG11201809793UA (en) 2016-05-09 2018-12-28 Bristol Myers Squibb Co Tl1a antibodies and uses thereof
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
CR20210094A (es) 2016-10-13 2021-03-31 Massachusetts Inst Technology ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
SI3766343T1 (sl) * 2016-11-04 2022-06-30 Regeneron Pharmaceuticals, Inc. Nehumane živali z modificiranim lokusom lahke verige lambda imunoglobulina
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
DK3720279T3 (da) 2017-12-05 2022-10-24 Regeneron Pharma Mus med et modificeret immunoglobulin-Lambda-letkæde og anvendelser deraf
CN111886255A (zh) 2018-01-12 2020-11-03 百时美施贵宝公司 抗tim3抗体及其用途
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US11576984B2 (en) 2018-03-26 2023-02-14 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
KR102480493B1 (ko) * 2018-06-08 2022-12-21 크리스탈 바이오사이언스 주식회사 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
CA3103646C (en) 2018-06-14 2023-06-27 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
CN112969929A (zh) 2018-10-26 2021-06-15 日本汽车能源株式会社 电池控制装置
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
BR112021023683A2 (pt) * 2019-06-05 2022-02-01 Regeneron Pharma Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
CN114554841A (zh) * 2019-07-01 2022-05-27 特里安尼公司 转基因哺乳动物及其使用方法
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CN115988960A (zh) * 2020-06-25 2023-04-18 株式会社湖美宝 杂合转基因动物
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
KR20230124594A (ko) 2020-12-23 2023-08-25 리제너론 파마슈티칼스 인코포레이티드 막관통 단백질 및 이를 생산하는 세포에 결합하는 항체를 수득하는 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE378403T1 (de) * 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CN100448992C (zh) * 2001-05-11 2009-01-07 麒麟医药株式会社 含人抗体λ轻链基因的人类人工染色体
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DK2319301T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
KR101397851B1 (ko) * 2004-08-05 2014-05-22 제넨테크, 인크. 인간화 항-ｃｍｅｔ 길항제
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US8084024B2 (en) * 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
EP2069403B1 (en) * 2006-10-02 2014-05-07 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
US8012714B2 (en) * 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
CA3038954A1 (en) * 2008-09-30 2010-04-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN102292445A (zh) * 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
LT3241435T (lt) * 2009-07-08 2021-10-25 Kymab Limited Gyvūnų modeliai ir terapinės molekulės
MX350983B (es) * 2010-02-08 2017-09-27 Regeneron Pharma Raton de cadena ligera comun.
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
NO2905338T3 (lt) * 2010-06-22 2017-12-30

Also Published As

Publication number Publication date
US9006511B2 (en) 2015-04-14
US9540452B2 (en) 2017-01-10
RS55037B1 (sr) 2016-12-30
KR101991234B1 (ko) 2019-06-20
ZA201506598B (en) 2017-03-29
JP5988969B2 (ja) 2016-09-07
AU2011271043A8 (en) 2016-01-21
CN104404050A (zh) 2015-03-11
CN104342455A (zh) 2015-02-11
CA2804311C (en) 2017-09-12
SI2568049T1 (sl) 2016-10-28
NZ707198A (en) 2016-04-29
US9029628B2 (en) 2015-05-12
IL244450A (en) 2017-11-30
US20150246977A1 (en) 2015-09-03
PL2568049T3 (pl) 2017-03-31
HK1183321A1 (zh) 2013-12-20
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
NZ627119A (en) 2015-05-29
JP2016010415A (ja) 2016-01-21
HUE029692T2 (en) 2017-03-28
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
JP6963542B2 (ja) 2021-11-10
RU2590594C2 (ru) 2016-07-10
US9150662B2 (en) 2015-10-06
HRP20160865T1 (hr) 2016-10-07
US20130323790A1 (en) 2013-12-05
KR20190142436A (ko) 2019-12-26
LT2480675T (lt) 2016-10-10
ES2570131T3 (es) 2016-05-17
SI2905338T1 (sl) 2017-12-29
BR112012032991A8 (pt) 2020-09-29
JP6545773B2 (ja) 2019-07-17
PT3034608T (pt) 2019-05-28
SMT201600229B (lt) 2016-08-31
KR20230036157A (ko) 2023-03-14
ME03386B (me) 2020-01-20
KR101970944B1 (ko) 2019-04-23
CA2803864A1 (en) 2011-12-29
EP3456832A1 (en) 2019-03-20
CY1117537T1 (el) 2017-04-26
MY195212A (en) 2023-01-11
TR201905992T4 (tr) 2019-05-21
KR102211911B1 (ko) 2021-02-05
IL247386A (en) 2017-07-31
EP2905338B8 (en) 2018-01-24
SMT201600212B (it) 2016-08-31
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
HUE029691T2 (en) 2017-03-28
AU2011271046B2 (en) 2015-10-01
EP2480675B1 (en) 2016-04-06
HK1226766A1 (zh) 2017-10-06
US20150173332A1 (en) 2015-06-25
PT2905338T (pt) 2017-11-10
JP2023133554A (ja) 2023-09-22
US20150089680A1 (en) 2015-03-26
KR20190073584A (ko) 2019-06-26
SG186391A1 (en) 2013-01-30
RS58736B1 (sr) 2019-06-28
US9394373B2 (en) 2016-07-19
US20160057979A1 (en) 2016-03-03
SI2480675T1 (sl) 2016-08-31
KR20200064166A (ko) 2020-06-05
CN104342455B (zh) 2017-05-31
ME02444B (me) 2016-09-20
MY194456A (en) 2022-11-30
PL2905338T3 (pl) 2018-01-31
AU2011271043A9 (en) 2015-10-01
MY195217A (en) 2023-01-11
RS56589B1 (sr) 2018-02-28
DK3034608T3 (da) 2019-05-06
IL259965B (en) 2019-02-28
HUE030285T2 (en) 2017-05-29
MY165287A (en) 2018-03-21
MX2022002117A (es) 2022-03-17
IL291301B2 (en) 2023-07-01
KR101934852B1 (ko) 2019-01-04
JP2018023403A (ja) 2018-02-15
EP2568049A1 (en) 2013-03-13
HK1170766A1 (zh) 2013-03-08
CN103068994B (zh) 2016-01-20
US20150320023A1 (en) 2015-11-12
KR20210073609A (ko) 2021-06-18
EP2568049B1 (en) 2016-04-13
KR20190014578A (ko) 2019-02-12
ME02902B (me) 2018-04-20
US9035128B2 (en) 2015-05-19
HUE044001T2 (hu) 2019-09-30
KR20180135996A (ko) 2018-12-21
JP6009441B2 (ja) 2016-10-19
KR102462042B1 (ko) 2022-11-03
CY1119478T1 (el) 2018-03-07
IL291301B1 (en) 2023-03-01
DK2905338T3 (da) 2017-11-06
US20160060359A1 (en) 2016-03-03
AU2011271043A1 (en) 2013-01-31
JP6341972B2 (ja) 2018-06-13
MX347322B (es) 2017-04-21
BR112012032991A2 (pt) 2015-10-06
KR102506001B1 (ko) 2023-03-07
JP2016010417A (ja) 2016-01-21
MX2012015300A (es) 2013-05-01
US20150246976A1 (en) 2015-09-03
JP6073441B2 (ja) 2017-02-01
RU2016119423A3 (lt) 2019-11-19
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
IL255179B (en) 2018-06-28
CN103068994A (zh) 2013-04-24
CA2804311A1 (en) 2011-12-29
US20150351371A1 (en) 2015-12-10
US9066502B2 (en) 2015-06-30
MX336344B (es) 2016-01-15
ES2646052T3 (es) 2017-12-11
SG10201504568YA (en) 2015-07-30
EP2480675A1 (en) 2012-08-01
CY1122877T1 (el) 2021-05-05
IL300712A (en) 2023-04-01
KR102001430B1 (ko) 2019-07-18
JP2020062061A (ja) 2020-04-23
JP6243384B2 (ja) 2017-12-06
PT2480675T (pt) 2016-07-11
RU2013102596A (ru) 2014-07-27
EP2905338A1 (en) 2015-08-12
MY195214A (en) 2023-01-11
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
CA2803864C (en) 2017-05-16
US9206261B2 (en) 2015-12-08
US20190203171A1 (en) 2019-07-04
SG10201504324UA (en) 2015-07-30
US9163092B2 (en) 2015-10-20
US20140137275A1 (en) 2014-05-15
JP2017012204A (ja) 2017-01-19
SMT201600213B (it) 2016-08-31
HUE036597T2 (hu) 2018-07-30
AU2011271046A1 (en) 2013-01-31
KR20190049932A (ko) 2019-05-09
ZA201404601B (en) 2016-02-24
US9334333B2 (en) 2016-05-10
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
JP2013531501A (ja) 2013-08-08
IL223719A (en) 2016-10-31
JP2019033765A (ja) 2019-03-07
PL2480676T3 (pl) 2016-10-31
RU2013102595A (ru) 2014-07-27
US20200239837A1 (en) 2020-07-30
US9844212B2 (en) 2017-12-19
JP2018201528A (ja) 2018-12-27
MX347318B (es) 2017-04-21
IL244450A0 (en) 2016-04-21
HRP20190807T1 (hr) 2019-08-23
HRP20171666T1 (hr) 2017-12-15
MY157477A (en) 2016-06-15
CN103068993B (zh) 2016-01-06
IL223720A (en) 2017-05-29
NZ707200A (en) 2016-04-29
IL282872A (en) 2021-06-30
CY1117692T1 (el) 2017-05-17
US20130326647A1 (en) 2013-12-05
JP2017006152A (ja) 2017-01-12
HRP20160794T1 (hr) 2016-08-12
KR102266097B1 (ko) 2021-06-18
IL255179A0 (en) 2017-12-31
NO2905338T3 (lt) 2017-12-30
KR102193823B1 (ko) 2020-12-22
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
SG186390A1 (en) 2013-01-30
PL3034608T3 (pl) 2019-08-30
US20150173331A1 (en) 2015-06-25
IL259965A (en) 2018-07-31
ES2576928T3 (es) 2016-07-12
RS55042B1 (sr) 2016-12-30
ME02440B (me) 2016-09-20
EP2480676B1 (en) 2016-04-06
EP3034608A1 (en) 2016-06-22
US9226484B2 (en) 2016-01-05
US20170258059A1 (en) 2017-09-14
US9850462B2 (en) 2017-12-26
KR20210013376A (ko) 2021-02-03
RU2724736C2 (ru) 2020-06-25
US20190153384A1 (en) 2019-05-23
KR101945352B1 (ko) 2019-02-07
IL269078A (en) 2019-11-28
US9399683B2 (en) 2016-07-26
MX348942B (es) 2017-07-04
DK2568049T3 (en) 2016-08-01
ZA201404600B (en) 2015-09-30
US9206262B2 (en) 2015-12-08
KR20220150430A (ko) 2022-11-10
US20120070861A1 (en) 2012-03-22
JP7236409B2 (ja) 2023-03-09
KR20200143511A (ko) 2020-12-23
ME02442B (me) 2016-09-20
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
SI2480676T1 (sl) 2016-10-28
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
LT2905338T (lt) 2017-12-27
KR20180135997A (ko) 2018-12-21
CN104404050B (zh) 2018-06-08
JP2021061863A (ja) 2021-04-22
NZ605751A (en) 2014-10-31
CN103068993A (zh) 2013-04-24
PT2480676E (pt) 2016-06-09
NZ605758A (en) 2014-08-29
IL291301A (en) 2022-05-01
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
DK2480675T3 (en) 2016-08-01
KR102059909B1 (ko) 2019-12-27
NZ626979A (en) 2015-05-29
WO2011163314A1 (en) 2011-12-29
KR20130027555A (ko) 2013-03-15
RS54891B1 (sr) 2016-10-31
BR112012032991B1 (pt) 2021-08-10
US20170107484A1 (en) 2017-04-20
KR102118565B1 (ko) 2020-06-03
ES2575223T3 (es) 2016-06-27
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
RU2601297C2 (ru) 2016-10-27
HRP20160497T1 (hr) 2016-07-15
IL264634B (en) 2019-09-26
US20150176002A1 (en) 2015-06-25
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
CY1118126T1 (el) 2017-06-28
JP2020128440A (ja) 2020-08-27
BR112012033248A2 (pt) 2017-11-28
EP3205726A1 (en) 2017-08-16
EP2480676A1 (en) 2012-08-01
US9012717B2 (en) 2015-04-21
EP3034608B1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
IL290085A (en) A common light chain mouse
ZA201404600B (en) Hybrid light chain mice
EP2609366A4 (en) LIGHT FUNCTION
GB2478365B (en) Light
TWM387201U (en) Light
AU330289S (en) Light
AU329890S (en) Light
AU330656S (en) Vehicle light
GB201004506D0 (en) Light snack